{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:48:58Z","timestamp":1779896938425,"version":"3.53.1"},"reference-count":103,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Cardiovascular disease, particularly coronary artery disease, is the leading cause of death in humans worldwide. Coronary heart disease caused by chemotherapy affects the prognosis and survival of patients with tumors. The most effective chemotherapeutic drugs for cancer include proteasome inhibitors, tyrosine kinase inhibitors, immune checkpoint inhibitors, 5-fluorouracil, and anthracyclines. Animal models and clinical trials have consistently shown that chemotherapy is closely associated with coronary events and can cause serious adverse cardiovascular events. Adverse cardiovascular events after chemotherapy can affect the clinical outcome, treatment, and prognosis of patients with tumors. In recent years, with the development of new chemotherapeutic drugs, new discoveries have been made about the effects of drugs used for chemotherapy on cardiovascular disease and its related mechanisms, such as inflammation. This review article summarizes the effects of chemotherapeutic drugs on coronary artery disease and its related mechanisms to guide efforts in reducing cardiovascular adverse events during tumor chemotherapy, preventing the development of coronary heart disease, and designing new prevention and treatment strategies for cardiotoxicity caused by clinical tumor chemotherapy.<\/jats:p>","DOI":"10.3389\/fcvm.2023.1118002","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T05:57:50Z","timestamp":1674107870000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Coronary atherosclerosis and chemotherapy: From bench to bedside"],"prefix":"10.3389","volume":"10","author":[{"given":"Fanghui","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dechun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjb4606","article-title":"Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the childhood cancer survivor study cohort.","volume":"339","author":"Mulrooney","year":"2009","journal-title":"BMJ."},{"key":"B2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1136\/hrt.2007.136093","article-title":"Anthracycline associated cardiotoxicity in survivors of childhood cancer.","volume":"94","author":"Lipshultz","year":"2008","journal-title":"Heart."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1200\/JCO.2010.33.4730","article-title":"High risk of symptomatic cardiac events in childhood cancer survivors.","volume":"30","author":"van der Pal","year":"2012","journal-title":"J Clin Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1038\/s41591-019-0590-4","article-title":"Single-cell immune landscape of human atherosclerotic plaques.","volume":"25","author":"Fernandez","year":"2019","journal-title":"Nat Med."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aay1863","article-title":"Targeted deletion of PD-1 in myeloid cells induces antitumor immunity.","volume":"5","author":"Strauss","year":"2020","journal-title":"Sci Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1172\/JCI31344","article-title":"Proatherogenic immune responses are regulated by the PD-1\/PD-L pathway in mice.","volume":"117","author":"Gotsman","year":"2007","journal-title":"J Clin Invest."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors.","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.cjca.2018.03.012","article-title":"Cardiac complications associated with checkpoint inhibition: a systematic review of the literature in an important emerging area.","volume":"34","author":"Mir","year":"2018","journal-title":"Can J Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors.","volume":"125","author":"Valent","year":"2015","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6616265","article-title":"Assessment and management of cardiotoxicity in hematologic malignancies.","volume":"2021","author":"Bojan","year":"2021","journal-title":"Dis Markers."},{"key":"B11","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1161\/CIRCRESAHA.107.152959","article-title":"Chronic proteasome inhibition contributes to coronary atherosclerosis.","volume":"101","author":"Herrmann","year":"2007","journal-title":"Circ Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.15420\/icr.2019.12","article-title":"Coronary artery vasospasm induced by 5-fluorouracil: proposed mechanisms, existing management options and future directions.","volume":"14","author":"Chong","year":"2019","journal-title":"Interv Cardiol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101604","article-title":"Kinase inhibition in relapsed\/refractory leukemia and lymphoma settings: recent prospects into clinical investigations.","volume":"13","author":"Machado","year":"2021","journal-title":"Pharmaceutics."},{"key":"B14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.hfc.2011.03.001","article-title":"A historical perspective of anthracycline cardiotoxicity.","volume":"7","author":"Ewer","year":"2011","journal-title":"Heart Fail Clin."},{"key":"B15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1200\/JCO.2005.03.5956","article-title":"Anthracyclines cause endothelial injury in pediatric cancer patients: a pilot study.","volume":"24","author":"Chow","year":"2006","journal-title":"J Clin Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jvs.2009.06.022","article-title":"In vivo human lower extremity saphenous vein bypass grafts manifest flow mediated vasodilation.","volume":"50","author":"Owens","year":"2009","journal-title":"J Vasc Surg."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.778762","article-title":"Imaging assessment of endothelial function: an index of cardiovascular health.","volume":"9","author":"Minhas","year":"2022","journal-title":"Front Cardiovasc Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/s41409-018-0155-z","article-title":"Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation.","volume":"53","author":"Duncan","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"B19","first-page":"138","article-title":"Dyslipidemia and atherosclerosis.","volume":"69","author":"Koba","year":"2011","journal-title":"Nihon Rinsho."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s12032-010-9593-1","article-title":"Intima-media thickness, myocardial perfusion, and laboratory risk factors of atherosclerosis in patients with breast cancer treated with anthracycline-based chemotherapy.","volume":"28","author":"Kal\u00e1bov\u00e1","year":"2011","journal-title":"Med Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/nop2.1059","article-title":"Cardiovascular status of breast cancer patients before and after receiving anthracycline chemotherapy regimen.","volume":"9","author":"Dong","year":"2022","journal-title":"Nurs Open."},{"key":"B22","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1080\/1120009X","article-title":"Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy increases carotid intima-media thickness and plaque score with von Willebrand factor activity elevation in patients with malignant lymphoma.","volume":"34","author":"Shimizu","year":"2022","journal-title":"J Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque.","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation."},{"key":"B24","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.21037\/tlcr","article-title":"Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis.","volume":"6","author":"Hu","year":"2017","journal-title":"Transl Lung Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejca","article-title":"Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study.","volume":"120","author":"Bar","year":"2019","journal-title":"Eur J Cancer."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors.","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity.","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-91439-8_1","article-title":"Imatinib mesylate.","volume":"201","author":"Waller","year":"2014","journal-title":"Recent Results Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052815","article-title":"Cardiotoxicity induced by protein kinase inhibitors in patients with cancer.","volume":"23","author":"Grela-Wojewoda","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/gm206","article-title":"The pharmacogenetics of imanitib.","volume":"2","author":"Dulucq","year":"2010","journal-title":"Genome Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia.","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia."},{"key":"B33","doi-asserted-by":"publisher","first-page":"383","DOI":"10.4239\/wjd.v12.i4.383","article-title":"Diabetic heart disease: a clinical update.","volume":"12","author":"Rajbhandari","year":"2021","journal-title":"World J Diabetes."},{"key":"B34","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","article-title":"Vascular toxicities of cancer therapies: the old and the new\u2013an evolving avenue.","volume":"133","author":"Herrmann","year":"2016","journal-title":"Circulation."},{"key":"B35","doi-asserted-by":"publisher","first-page":"531","DOI":"10.4149\/BLL_2021_085","article-title":"Cardiovascular events and atherogenic lipid profile in chronic myeloid leukemia patients treated with nilotinib versus imatinib.","volume":"122","author":"Petrikova","year":"2021","journal-title":"Bratisl Lek Listy."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1200\/JCO","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.","volume":"28","author":"Choueiri","year":"2010","journal-title":"J Clin Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood."},{"key":"B38","doi-asserted-by":"publisher","first-page":"18895","DOI":"10.1073\/pnas.0810246105","article-title":"Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice.","volume":"105","author":"Louvet","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B39","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1161\/01.ATV.0000124105.39900.db","article-title":"Imatinib attenuates diabetes-associated atherosclerosis.","volume":"24","author":"Lassila","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1097\/HJH.0000000000003191","article-title":"Inhibition of platelet-derived growth factor pathway suppresses tubulointerstitial injury in renal congestion.","volume":"40","author":"Matsuki","year":"2022","journal-title":"J Hypertens."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd9030066","article-title":"Cardiotoxicity of non-anthracycline cancer chemotherapy agents.","volume":"9","author":"Briasoulis","year":"2022","journal-title":"J Cardiovasc Dev Dis."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092540","article-title":"Non-hematologic toxicity of bortezomib in multiple myeloma: the neuromuscular and cardiovascular adverse effects.","volume":"12","author":"Pancheri","year":"2020","journal-title":"Cancers."},{"key":"B43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.5115\/acb.2016.49.2.99","article-title":"Changes in expression of proteasome in rats at different stages of atherosclerosis.","volume":"49","author":"Ismawati","year":"2016","journal-title":"Anat Cell Biol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s12185-010-0586-9","article-title":"Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma.","volume":"91","author":"Takamatsu","year":"2010","journal-title":"Int J Hematol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/bjh.14708","article-title":"A retrospective analysis of 3954 patients in phase 2\/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.","volume":"178","author":"Laubach","year":"2017","journal-title":"Br J Haematol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma.","volume":"37","author":"Cornell","year":"2019","journal-title":"J Clin Oncol."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis.","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/1871529X21666210412113017","article-title":"Incidence and management of carfilzomib-induced cardiovascular toxicity; A systematic review and meta-analysis.","volume":"21","author":"Latif","year":"2021","journal-title":"Cardiovasc Hematol Disord Drug Targets."},{"key":"B49","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ajh.24608","article-title":"Ixazomib cardiotoxicity: a possible class effect of proteasome inhibitors.","volume":"92","author":"Jouni","year":"2017","journal-title":"Am J Hematol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1042\/CS20190139","article-title":"In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline.","volume":"133","author":"Pokorna","year":"2019","journal-title":"Clin Sci."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918780140","article-title":"5-Fluorouracil and cardiotoxicity: a review.","volume":"10","author":"Sara","year":"2018","journal-title":"Ther Adv Med Oncol."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.924446","article-title":"5-Fluorouracil rechallenge after cardiotoxicity.","volume":"21","author":"Desai","year":"2020","journal-title":"Am J Case Rep."},{"key":"B53","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1517\/14740330902733961","article-title":"Fluoropyrimidine-associated cardiotoxicity: revisited.","volume":"8","author":"Saif","year":"2009","journal-title":"Expert Opin Drug Saf."},{"key":"B54","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00280-011-1669-x","article-title":"5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity.","volume":"69","author":"Jensen","year":"2012","journal-title":"Cancer Chemother Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1161\/CIRCULATIONAHA.109.907121","article-title":"Early atherosclerosis exhibits an enhanced procoagulant state.","volume":"122","author":"Borissoff","year":"2010","journal-title":"Circulation."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26824","article-title":"Rechallenging fluoropyrimidine-induced cardiotoxicity and neurotoxicity: a report of two cases.","volume":"14","author":"Ashish","year":"2022","journal-title":"Cureus."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27917","article-title":"Breast cancer and the cardiovascular disease: a narrative review.","volume":"14","author":"Cherukuri","year":"2022","journal-title":"Cureus."},{"key":"B58","first-page":"I51","article-title":"Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy\u2013a survey of 427 patients.","volume":"8","author":"Tsavaris","year":"2002","journal-title":"Med Sci Monit."},{"key":"B59","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000072334","article-title":"High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients.","volume":"65","author":"Wacker","year":"2003","journal-title":"Oncology."},{"key":"B60","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3904\/kjim.2012.27.3.342","article-title":"A case of severe coronary spasm associated with 5-fluorouracil chemotherapy.","volume":"27","author":"Kim","year":"2012","journal-title":"Korean J Intern Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s00059-010-3367-6","article-title":"Acute myocardial infarction in a patient with chronic myelocytic leukemia during chemotherapy with hydroxyurea.","volume":"35","author":"K\u00e4lsch","year":"2010","journal-title":"Herz."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s00421-022-05040-z","article-title":"Association between atherogenic risk-modulating proteins and endothelium-dependent flow-mediated dilation in coronary artery disease patients.","author":"Tryfonos","year":"2022","journal-title":"Eur J Appl Physiol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.tem.2018.04.007","article-title":"Atherosclerosis is an epigenetic disease.","volume":"29","author":"Xu","year":"2018","journal-title":"Trends Endocrinol Metab."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-022-04605-7","article-title":"Anthracycline-induced cardiotoxicity and cell senescence: new therapeutic option?","volume":"79","author":"Seara","year":"2022","journal-title":"Cell Mol Life Sci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1161\/01.CIR.0000130172.62481.90","article-title":"In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation: a clue to the understanding of the mechanisms of thrombotic plaque erosion.","volume":"109","author":"Durand","year":"2004","journal-title":"Circulation."},{"key":"B66","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/cvr\/cvab053","article-title":"Coronary microcirculation damage in anthracycline cardiotoxicity.","volume":"118","author":"Gal\u00e1n-Arriola","year":"2022","journal-title":"Cardiovasc Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","article-title":"Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation.","volume":"31","author":"Bu","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1111\/bph.13802","article-title":"Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis.","volume":"174","author":"Foks","year":"2017","journal-title":"Br J Pharmacol."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/cells9091987","article-title":"Antibody-mediated inhibition of CTLA4 aggravates atherosclerotic plaque inflammation and progression in hyperlipidemic mice.","volume":"9","author":"Poels","year":"2020","journal-title":"Cells."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.ijcard.2012.12.085","article-title":"T-cell co-stimulation by CD28-CD80\/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development.","volume":"168","author":"Ewing","year":"2013","journal-title":"Int J Cardiol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jaccao.2020.08.007","article-title":"Immune checkpoint inhibitor therapy aggravates T cell-driven plaque inflammation in atherosclerosis.","volume":"2","author":"Poels","year":"2020","journal-title":"JACC CardioOncol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","article-title":"Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels.","volume":"56","author":"Kappers","year":"2010","journal-title":"Hypertension."},{"key":"B73","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","article-title":"Extended kinase profile and properties of the protein kinase inhibitor nilotinib.","volume":"1804","author":"Manley","year":"2010","journal-title":"Biochim Biophys Acta."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0002-9440(10)63716-9","article-title":"Role of discoidin domain receptors 1 and 2 in human smooth muscle cell-mediated collagen remodeling: potential implications in atherosclerosis and lymphangioleiomyomatosis.","volume":"164","author":"Ferri","year":"2004","journal-title":"Am J Pathol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1161\/CIRCRESAHA.109.207357","article-title":"Discoidin domain receptor 1 on bone marrow-derived cells promotes macrophage accumulation during atherogenesis.","volume":"105","author":"Franco","year":"2009","journal-title":"Circ Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1161\/CIRCRESAHA.109.213637","article-title":"Increased cell and matrix accumulation during atherogenesis in mice with vessel wall-specific deletion of discoidin domain receptor 1.","volume":"106","author":"Franco","year":"2010","journal-title":"Circ Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1038\/leu.2017.245","article-title":"Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.","volume":"31","author":"Hadzijusufovic","year":"2017","journal-title":"Leukemia."},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168960","article-title":"Effects of primary mast cell disease on hemostasis and erythropoiesis.","volume":"22","author":"Seidel","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.18632\/oncotarget.3074","article-title":"Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia.","volume":"6","author":"Cerny-Reiterer","year":"2015","journal-title":"Oncotarget."},{"key":"B80","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/978-981-16-4254-8_14","article-title":"Store-operated calcium entry in the cardiovascular system.","volume":"1349","author":"Liu","year":"2021","journal-title":"Adv Exp Med Biol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR signaling in cancer.","volume":"21","author":"Touat","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B82","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell."},{"key":"B83","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1517\/14740338.2013.788642","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors.","volume":"12","author":"Mouhayar","year":"2013","journal-title":"Expert Opin Drug Saf."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-00931-w","article-title":"Proteasome inhibitor-related cardiotoxicity: mechanisms, diagnosis, and management.","volume":"22","author":"Wu","year":"2020","journal-title":"Curr Oncol Rep."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.","volume":"114","author":"Hideshima","year":"2009","journal-title":"Blood."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1515\/CCLM.2006.209","article-title":"Inhibition of the ubiquitin-proteasome system: a new avenue for atherosclerosis.","volume":"44","author":"Tan","year":"2006","journal-title":"Clin Chem Lab Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"633","DOI":"10.52547\/rbmb.10.4.633","article-title":"Effect of proteasome inhibitor on vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) expressions in rat model of atherosclerosis.","volume":"10","author":"Ismawati","year":"2022","journal-title":"Rep Biochem Mol Biol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1161\/01.atv.0000051384.43104.fc","article-title":"Endothelial dysfunction: a marker of atherosclerotic risk.","volume":"23","author":"Bonetti","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/CMAR.S273544","article-title":"Managing 5FU cardiotoxicity in colorectal cancer treatment.","volume":"14","author":"Anaka","year":"2022","journal-title":"Cancer Manag Res."},{"key":"B90","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1001\/jamacardio2016.3841","article-title":"A population-based study of cardiovascular mortality following early-stage breast cancer.","volume":"2","author":"Abdel-Qadir","year":"2017","journal-title":"JAMA Cardiol."},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-337","article-title":"Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.","volume":"10","author":"Smith","year":"2010","journal-title":"BMC Cancer."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2165\/00003495-200565070-00008","article-title":"Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy.","volume":"65","author":"Cvetkovic","year":"2005","journal-title":"Drugs."},{"key":"B93","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity.","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis.","volume":"321","author":"Zheng","year":"2019","journal-title":"J Am Med Assoc."},{"key":"B95","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jjcc.2018.02.011","article-title":"Mechanism and management of cancer-associated thrombosis.","volume":"72","author":"Mukai","year":"2018","journal-title":"J Cardiol."},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/ph15081007","article-title":"Pharmaceutical prevention and management of cardiotoxicity in hematological malignancies.","volume":"15","author":"Perpinia","year":"2022","journal-title":"Pharmaceuticals."},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2022.1430","article-title":"Cancer and cardiovascular disease: can understanding the mechanisms of cardiovascular injury guide us to optimise care in cancer survivors?","volume":"16","author":"Truong","year":"2022","journal-title":"Ecancermedicalscience."},{"key":"B98","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2174\/138161209787315684","article-title":"Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy.","volume":"15","author":"Zhou","year":"2009","journal-title":"Curr Pharm Des."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/S0140-6736(16)31679-8","article-title":"Global, regional, and national comparative risk assessment of 79 behavioral, environmental, and occupational, and metabolic risks or clusters of risks, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015.","volume":"388","year":"2015","journal-title":"Lancet."},{"key":"B100","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1.","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab."},{"key":"B102","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1161\/01.ATV.0000143933.20616.1b","article-title":"Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice.","volume":"24","author":"Br\u00e5n\u00e9n","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-016-0521-1","article-title":"Fluoropyrimidine-induced cardiotoxicity: manifestations, mechanisms, and management.","volume":"18","author":"Layoun","year":"2016","journal-title":"Curr Oncol Rep."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1118002\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T05:57:55Z","timestamp":1674107875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1118002\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":103,"alternative-id":["10.3389\/fcvm.2023.1118002"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1118002","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]},"article-number":"1118002"}}